Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.

Abstract

Patients with high-risk acute promyelocytic leukemia (APL) have inferior outcomes compared with patients with low-risk APL, predominantly due to higher risk of early mortality related to hemorrhage. The majority of regimens contain prolonged maintenance, but the impact of this phase is not clear in the era of all trans retinoic acid (ATRA) and arsenic trioxide (ATO). We present a retrospective analysis of 10 patients that were treated for high risk APL based on the consolidation treatment phase of APL 0406 study without subsequent maintenance. With a median follow up of 38 months, all patients remain in remission.

• Authors: Gaurav Shah, Fady M Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P Erba, Nikolaos Papadantonakis
• Journal: Hematology/oncology and stem cell therapy (Hematol Oncol Stem Cell Ther) Vol. 13 Issue 3 Pg. 143-146 (Sep 2020) ISSN: 2589-0646 [Electronic] Saudi Arabia
• PMID: 31629725 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Tretinoin
• Arsenic Trioxide

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Arsenic Trioxide (administration & dosage, adverse effects)
• Disease-Free Survival
• Female
• Follow-Up Studies
• Humans
• Leukemia, Promyelocytic, Acute (drug therapy, mortality)
• Male
• Middle Aged
• Retrospective Studies
• Risk Factors
• Survival Rate
• Tretinoin (administration & dosage, adverse effects)